Non-Hodgkin's Lymphoma (NHL) Clinical Trial
Official title:
A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL
According to amendment 3 this study addresses the question if intensification of administration of rituximab in standard treatment for patients with newly diagnosed aggressive B-Non Hodgkin Lymphoma (B-NHL) and high risk (aaIPI 2 or 3) results in a better time to treatment failure (TTTF)
This study was primarily designed to compare aggressive conventional chemotherapy with a repetitive high-dose (HD) therapy program using identical, effective drugs at highest possible dose and dose intensity with/without addition of rituximab (initially 4 treatment arms). In 2004 the first amendment had to be added in order to close two treatment arms without rituximab due to recent data revealing a significant advantage for rituximab-treated patients with CD20+lymphoma. A planned interim analysis in 2010 revealed inferiority of the high-dose treatment thus in the 2nd amendment the high-dose arm was closed and additionally the rituximab frequency was raised from 6 to 12 administrations as recent publications gave hint for advantage. The last amendment was added in 2010 to adjust for delayed recruitment mainly due to organisation problems. As the high-dose arm was closed only CD20+ B-lymphoma were included past amendment 2. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01448928 -
Zevalin Post-marketing Surveillance in Japan
|
||
| Terminated |
NCT00089284 -
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
|
Phase 1/Phase 2 | |
| Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01758042 -
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
|
N/A | |
| Terminated |
NCT00185679 -
Haploid Allogeneic Transplant Using the CliniMACS System
|
Phase 2 | |
| Completed |
NCT01108341 -
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 2 | |
| Completed |
NCT01527838 -
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
|
Phase 1 | |
| Completed |
NCT00614042 -
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Completed |
NCT00923910 -
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
|
Phase 1/Phase 2 | |
| Completed |
NCT02071888 -
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
|
Phase 1 | |
| Recruiting |
NCT04696705 -
Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients
|
Early Phase 1 | |
| Completed |
NCT01479387 -
Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan
|
N/A | |
| Completed |
NCT00889798 -
Tumor Registry of Lymphatic Neoplasia
|
||
| Terminated |
NCT05144347 -
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
|
Phase 1 |